We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cosopt Versus Xalatan

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00273429
First Posted: January 9, 2006
Last Update Posted: January 9, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Pharmaceutical Research Network
  Purpose
To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.

Condition Intervention Phase
Open-Angle Glaucoma Ocular Hypertension Drug: timolol maleate 0.5% Drug: dorzolamide/timolol maleate fixed combination Drug: latanoprost 0.005% Drug: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Pharmaceutical Research Network:

Study Start Date: April 2005
Estimated Study Completion Date: December 2005
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular hypertenstion
  • intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H
  • ETDRS visual acuity must be 1.0 or better in both eyes

Exclusion Criteria:

  • any contraindications to study medications
  • any anticipated change in systemic hypertensive therapy during the trial
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273429


Locations
United States, Florida
Central Florida Eye Associates
Lakeland, Florida, United States, 33805
United States, Illinois
Midwest Eye Center SC
Bourbonnais, Illinois, United States, 60914
Sponsors and Collaborators
Pharmaceutical Research Network
Investigators
Study Director: William C. Stewart, MD Pharmaceutical Research Network, LLC
Principal Investigator: Jay Mulaney, MD Central Florida Eye Associates
Principal Investigator: Sriram Sonty, MD, FACS Midwest Eye Center SC
  More Information

ClinicalTrials.gov Identifier: NCT00273429     History of Changes
Other Study ID Numbers: PRN 04-015
First Submitted: January 6, 2006
First Posted: January 9, 2006
Last Update Posted: January 9, 2007
Last Verified: January 2007

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Glaucoma
Eye Diseases
Timolol
Latanoprost
Dorzolamide
Maleic acid
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Enzyme Inhibitors
Carbonic Anhydrase Inhibitors